Advertisement

CNS Stimulants and Athletic Performance

  • Galen R. Wenger

Abstract

In an effort to find a short cut that will reduce the time and effort required to become competitive or to meet the challenge of the moment, it has been all too common an occurrence in the history of man to try chemicals of various types to improve both mental and physical performance. Examples of this range from students trying to obtain a better grade, to athletes trying to shave seconds off the time required to perform an athletic feat, to the military’s use of chemicals to help soldiers perform heroic feats of endurance in an effort to defeat the enemy. The first reported use of drugs to increase or improve athletic performance predates the birth of Christ. It is reported in the writings of Homer that Greek athletes consumed mushrooms prior to athletic events to improve their performance. More recently, during the nineteenth century, there were widespread reports of athletes using caffeine, alcohol, nitroglycerine, ethyl ether, and opium.1 However, it was not until the unfortunate death of a Danish cyclist during the 1960 Olympic Games in Rome that the attention of the world was drawn to this serious problem. Today, drug use by athletes involves several classes of drugs; however, this chapter will restrict itself to a discussion of the use of three drugs or drug classes: amphetamines, cocaine, and caffeine.

Keywords

Physical Performance Bicycle Ergometer Athletic Performance Caffeine Ingestion Work Output 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Puffer JC: The use of drugs in swimming. Clin Sports Med 5: 77–89, 1966.Google Scholar
  2. 2.
    Gilman AG, Goodman LS, Rail TW, et al (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 7. New York, MacMillan Publishing Co., 1985.Google Scholar
  3. 3.
    Tewes PA, Fischman MW: Effects of d-amphetamine and diazepam on fixed-interval, fixed-ratio responding in humans. J Pharmacol Exp Ther 221: 373–383, 1982.PubMedGoogle Scholar
  4. 4.
    Weiner N: Pharmacology of central nervous system stimulants, in Zarafonetis, CJD (ed): Drug Abuse: Proceedings of the International Conference. Philadelphia, Lea & Febiger, 1972, pp 243–251.Google Scholar
  5. 5.
    Bowman WC, Rand MJ: Textbook of Pharmacology, ed 2. Oxford, Blackwell Scientific, 1980.Google Scholar
  6. 6.
    Fischman MW, Schuster CR: Cocaine self-administration in humans. Fed Proc 41: 241–246, 1982.PubMedGoogle Scholar
  7. 7.
    Resnick RB, Kestenbaum RS, Schwartz LD: Acute systemic effects of cocaine in man: a controlled study by intranasal and intravenous routes. Science 195: 696–699, 1977.PubMedCrossRefGoogle Scholar
  8. 8.
    Fischman MW, Schuster CR, Resnekov L, et al: Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch Gen Psychiat 33: 938–989, 1976.CrossRefGoogle Scholar
  9. 9.
    Kossowsky WA, Lyon AF: Cocaine and acute myocardial infarction, a probable connection. Chest 86: 729–731, 1984.PubMedCrossRefGoogle Scholar
  10. 10.
    Posternack PF, Calvin SB, Bauman FG: Cocaine-induced angina pectoris and acute myocardial infarction in patients younger than 40 years. Am J Cardiol 55: 847, 1985.CrossRefGoogle Scholar
  11. 11.
    Van Dyke C, Jatlow P, Ungerer J, et al: Oral cocaine: plasma concentrations and central effects. Science 200: 211–213, 1978.PubMedCrossRefGoogle Scholar
  12. 12.
    Goldstein A, Warren R, Kaizer S: Psychotropic effects of caffeine in man. I. Individual differences in sensitivity to caffeine-induced wakefulness. J Pharmacol Exp Ther 149: 156–159, 1965.PubMedGoogle Scholar
  13. 13.
    Rosenblum D, Sutton JR: Drugs and exercise. Med Clin North Am 69: 177–187, 1985.Google Scholar
  14. 14.
    Rall TW: Evolution of the mechanism of action of methylxanthines: from calcium mobilizers to antagonists of adenosine receptors. Pharmacologist 24: 277–287, 1982.Google Scholar
  15. 15.
    Post RM: Central stimulants. Clinical and experimental evidence on tolerance and sensitization, in Israel Y, Glaser FB, Kalant H, et al (eds): Research Advances in Alcohol and Drug Problems. New York, Plenum Press, 1981, pp 1–65.Google Scholar
  16. 16.
    Post RM, Contel NR: Human and animal studies of cocaine: Implications for development of behavioral pathology, in Creese I (ed): Stimulants: Neurochemical, Behavioral, and Clinical Perspectives. New York, Raven Press, 1983, pp 169–203.Google Scholar
  17. 17.
    Demellweek C, Goudie AJ: Behavioral tolerance to amphetamine and other psychostimulants: the case for considering behavioral mechansims. Psychopharmacologia 80: 287–307, 1983.CrossRefGoogle Scholar
  18. 18.
    Barone JJ, Roberts H: Human consumption of caffeine, in Dews PB (ed): Caffeine. Berlin, Springer-Verlag, 1984, pp 59–73.CrossRefGoogle Scholar
  19. 19.
    Robertson D, Wade D, Workman R, et al: Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest 67: 1111–1117, 1981.PubMedCrossRefGoogle Scholar
  20. 20.
    Coyle EF: Ergogenic aids. Clin Sports Med 3: 731–742, 1984.PubMedGoogle Scholar
  21. 21.
    Laties VG, Weiss B: The amphetamine margin in sports. Fed Proc 40: 2689–2692, 1981.PubMedGoogle Scholar
  22. 22.
    Boje O: Doping Bull Health Org League of Nations 8: 439–369, 1939.Google Scholar
  23. 23.
    Venerando A: Doping pathology and ways to control it. Medicina dello Sport 3: 972–983, 1963.Google Scholar
  24. 24.
    Medical Commission of the British Commonwealth Games: Prevention and detection of drug taking (doping) at the IX British Commonwealth Games. Scot Med J 16: 364–368, 1971.Google Scholar
  25. 25.
    Fischbach E: The problem of doping. Med Monatsschr 26: 377–381, 1972.PubMedGoogle Scholar
  26. 26.
    Rivers W, Webber H: The action of caffeine on the capacity for muscular work. J Physiol 36: 33–47, 1907.PubMedGoogle Scholar
  27. 27.
    Seashore RH, Ivy AC: Effects of analeptic drugs in relieving fatigue. Psychol Monogr 67 (15): 1–16, 1953.CrossRefGoogle Scholar
  28. 28.
    Foltz E, Ivy A. Barborka C: The use of double work periods in the study of fatigue and the influence of caffeine. Am J Physiol 136: 79–86, 1942.Google Scholar
  29. 29.
    Foltz EE, Ivy AC, Barborka CJ: The influence of amphetamine (benzedrine) sulfate, d-desoxyephedrine hydrochloride (pervitin) and caffeine upon work output recovery when rapidly exhausting work is done by trained subjects. J Lab Clin Med 28: 603–605, 1943.Google Scholar
  30. 30.
    Asmussen E, Boje O: The effect of alcohol and some drugs on the capacity for work. Acta Physiol Scand 15: 109–113, 1948.PubMedCrossRefGoogle Scholar
  31. 31.
    Berglund B, Hemmingsson P: Effects of caffeine ingestion on exercise performance at low and high altitudes in cross-country skiers. Int J Sports Med 3: 234–236, 1982.PubMedCrossRefGoogle Scholar
  32. 32.
    McNaughton LR: The influence of caffeine ingestion on incremental treadmill running. Br J Sports Med 20: 109–112, 1986.PubMedCrossRefGoogle Scholar
  33. 33.
    Costill DK, Dalsky GP, Fink WJ: Effects of caffeine ingestion on metabolism and exercise performance. Med Sci Sports 10: 155–158, 1978.PubMedGoogle Scholar
  34. 34.
    Ivy JL, Costill DL, Fink WJ, et al: Influence of caffeine and carbohydrate feedings on endurance performance. Med Sci Sports 11: 6–11, 1979.PubMedGoogle Scholar
  35. 35.
    Fisher SM, McMurray RG, Berry M, et al: Influence of caffeine on exercise performance in habitual caffeine users. Mt J Sports Med 7: 276–280, 1986.Google Scholar
  36. 36.
    Foltz EE, Schiffrin MJ, Ivy AC: The influence of amphetamine (benzedrine) sulfate and caffeine on the performance of rapidly exhausting work by untrained subjects. J Lab Clin Med 28: 601–603, 1943.Google Scholar
  37. 37.
    Alles GA, Feigen GA: The influence of benzedrine on work decrement and patellar reflex. Am J Physiol 136: 392–400, 1942.Google Scholar
  38. 38.
    Haldi J, Wynn W: Action of drugs on the efficiency of swimmers. Research Quart 17: 96–101, 1946.Google Scholar
  39. 39.
    Ganslen RV, Balke B, Nagle F, et al: Effects of some tranquilizing, analeptic and vasodilating drugs on physical work capacity and orthostatic tolerance. Aerospace Med 35: 630–633, 1964.PubMedGoogle Scholar
  40. 40.
    Margaria R, Nghemo P, Rovelli E: The effect of some drugs on the maximal capacity of athletic performance in man. Mt Z Angew Physiol 20: 281–287, 1964.Google Scholar
  41. 41.
    Perkins R, Williams MH: Effect of caffeine upon maximal muscular endurance of females. Med Sci Sports 7: 221–224, 1975.PubMedGoogle Scholar
  42. 42.
    Powers SK, Byrd RJ, Tulley R, et al: Effects of caffeine ingestion on metabolism and performance during graded exercise. Eur J Physiol 50: 301–307, 1983.CrossRefGoogle Scholar
  43. 43.
    Bond V, Gresham K, McRae J, et al: Caffeine ingestion and isokinetic strength. Br J Sports Med 20: 135–137, 1986.PubMedCrossRefGoogle Scholar
  44. 44.
    Casal DC, Leon AS: Failure of caffeine to affect substrate utilization during prolonged running. Med Sci Sports Exerc 17: 174–179, 1985.PubMedCrossRefGoogle Scholar
  45. 45.
    O’Neil FT, Hynak-Hankinson MT, Gorman T: Research and application of current topics in sports nuitrition. J Am Diet Assoc 86: 1007–1015, 1986.PubMedGoogle Scholar
  46. 46.
    Lehman G, Straub H, Szakall A: Pervitin als leistungssteigerndes Mittel. Arbeitsphysiologie 10: 680691, 1939.Google Scholar
  47. 47.
    Heyrodt H, Weissenstein H: Uber Steigerung korperlicher Leistungfahigkeit durch Pervitin. Arch Exp Pathol Pharmakol 195: 273–275, 1940.CrossRefGoogle Scholar
  48. 48.
    Knoefel PK: The influence of phenisopropyl amine and phenisopropyl methyl amine on work output. Fed Proc 2: 83, 1943.Google Scholar
  49. 49.
    Somerville W: The effect of benzedrine on mental or physical fatigue in soldiers. Can Med Assoc J 55: 470–476, 1946.Google Scholar
  50. 50.
    Cuthbertson DP, Knox JAC: The effects of analeptics on the fatigued subject. J Physiol 106: 42–58, 1947.Google Scholar
  51. 51.
    Bujas Z, Petz B: Utjecaj fenamina na economicnast staticnog rada. Arh Hig Rada 6: 205–208, 1955.PubMedGoogle Scholar
  52. 52.
    Smith GM, Beecher HK: Amphetamine sulfate and athletic performance. I. Objective effects. JAMA 170: 542–557, 1959.CrossRefGoogle Scholar
  53. 53.
    Hurst PN, Radlow R, Bagley SK: The effects of D-amphetamine and chlordiazepoxide upon strength and estimated strength. Ergonomics 11: 47–52, 1968.PubMedCrossRefGoogle Scholar
  54. 54.
    Wyndham CH, Rogers GG, Benade MS, et al: Physiological effects of the amphetamines during exercise. S Afr Med J 45: 247–252, 1971.PubMedGoogle Scholar
  55. 55.
    Chandler JV, Blair SN: The effect of amphetamines on selected components related to athletic success. Med Sci Sports Exerc 12: 65–69, 1980.PubMedGoogle Scholar
  56. 56.
    Karpovich PV: Effect of amphetamine sulfate on athletic performance. JAMA 170: 558–561, 1959.CrossRefGoogle Scholar
  57. 57.
    Williams MH, Thompson J: Effect of variant dosages of amphetamine upon endurance. Research Quart 44: 417–422, 1973.Google Scholar
  58. 58.
    Smith GM, Beecher HK: Amphetamine, secobarbital, and athletic performance. II. Subjective evaluations of performances, mood states, and physical states. DAMA 172: 1502–1514, 1960.Google Scholar
  59. 59.
    Mandel AJ: The Nightmare Season. New York, Random House, 1976.Google Scholar
  60. 60.
    Mandel AJ, Stewart KD, Russo PV: The Sunday syndrome: From kinetics to altered consciousness. Fed Proc 40: 2693–2698, 1981.Google Scholar
  61. 61.
    Tyler DB: The effect of amphetamine sulfate and some barbiturates on the fatigue produced by prolonged wakefulness. Am J Physiol 150: 253–262, 1947.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1988

Authors and Affiliations

  • Galen R. Wenger
    • 1
  1. 1.Department of PharmacologyUniversity of Arkansas for Medical SciencesLittle RockUSA

Personalised recommendations